What is DYN (DYN) stock price today?

DYN (DYN) is currently trading at $25.97, up 2.89% today.

What is DYN P/E ratio?

DYN's P/E ratio is -6.05. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DYN return on equity (ROE)?

DYN's return on equity (ROE) is -58.89%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is DYN's market cap?

DYN has a market capitalization of $4.85B.

NASDAQ · Biotechnology

DYN (DYN) Stock

$25.97 +2.89% NASDAQ: DYN Healthcare

Valuation

Metric	Value
Price	$25.97
Market Cap	$4.85B
P/E Ratio	-6.05
P/B Ratio	3.12
P/S Ratio	0.00
EPS (TTM)	$-3.47
52-Week High	$25.97
52-Week Low	$8.06
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-58.89%
ROA	-32.70%
ROCE	-48.15%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	22.10

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-150.0M	$-171.0M	$-242.0M	$-344.0M	$-468.0M
Net Profit	$-149.0M	$-168.0M	$-236.0M	$-317.0M	$-446.0M
EPS	$-2.93	$-3.23	$-3.95	$-3.37	$-3.47
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$426.0M	$306.0M	$165.0M	$691.0M	$1.2B
Total Liabilities	$57.0M	$54.0M	$74.0M	$61.0M	$215.0M
Cash	$201.0M	$172.0M	$122.0M	$435.0M	$893.0M
Borrowings	$33.0M	$30.0M	$27.0M	$24.0M	$20.0M

Latest News

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? Motley Fool · Jul 4, 2026 Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? Motley Fool · Jul 1, 2026 Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Motley Fool · Jun 26, 2026 Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing MT Newswires · Jun 26, 2026 TD Cowen Initiates Dyne Therapeutics at Buy MT Newswires · Jun 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-120.0M	$-154.0M	$-188.0M	$-292.0M	$-403.0M
Investing Cash Flow	$-142.0M	$84.0M	$83.0M	$-206.0M	$-31.0M
Financing Cash Flow	$1.0M	$1.0M	$2.0M	$37.0M	$0
Net Cash Flow	$-100.0M	$-29.0M	$-51.0M	$313.0M	$458.0M
Free Cash Flow	$-123.0M	$-157.0M	$-189.0M	$-295.0M	$-405.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-4.76
FCF Yield	-15.23%
Quick Ratio	19.92
Interest Coverage	-78.00
Return 1Y	151.09%
Return 3Y	112.74%
Return 5Y	18.47%

Ownership

Insiders Held0.28%

Institutions Held115.65%

Institutions Float Held115.97%

Institutional Holder	Shares	Report Date
T. Rowe Price Investment Management, Inc.	30,785,801	2026-03-31
Janus Henderson Group PLC	13,647,376	2026-03-31
Blackrock Inc.	11,699,870	2026-03-31
Atlas Venture Life Science Advisors, LLC	9,130,465	2026-03-31
FMR, LLC	8,908,980	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPGAscentage Pharma Group International	$20.18	+4.89%	-9.87	$1.88B	0.00%
APGE	$134.19	+0.06%	-16.89	$8.30B	0.00%
CELC	$92.49	+5.44%	-91.68	$4.51B	0.00%
CGON	$72.17	-1.84%	-26.72	$6.37B	0.00%
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%	-22.75	$6.27B	0.00%

About DYN

DYN stock trades at $25.97 with a market capitalization of $4.85B. The stock is valued at a price-to-earnings (P/E) ratio of -6.05, price-to-book of 3.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.06 and $25.97, and currently trades at its 52-week high.

On profitability, DYN generates a return on equity (ROE) of -58.89%, return on capital employed of -48.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides